Biography:
Dr. Hong-Tao Li received his PhD degree in 2009 at Chinese Academy of Sciences. He got postdoctoral training in Shanghai Institute of Biochemistry and Cell Biology, China. Then he joined Dr. Gangning Liang’s lab in University of Southern California, where his study focus on cancer epigenetics and translational medicine.
Combination treatment of DNA Hypomethylating Agents targeting SETD2-defficient kidney cancer